Panacea Index Logo

Command Palette

Search for a command to run...

Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial.

Nutrition journal
January 1, 1970
Jennifer Erickson et al. (4 authors)
Journal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to assess the gastrointestinal tolerance of low FODMAP oral nutrition supplements, including a positive control with lactose-free milk, in healthy adults.

Results Summary

The positive control (lactose-free milk with FOS) resulted in higher breath hydrogen response compared to low FODMAP supplements, but there were no differences in GI symptom responses between treatments. All treatments were well tolerated in healthy participants.

Population

21 healthy adults aged 19-32 years.

Effective Dosage

5 g fructooligosaccharides (FOS) mixed in lactose-free milk (positive control).

Duration

Single consumption per visit with a one-week washout period between visits.

Interactions

None mentioned

Extracted Claims (5)
InterventionDirectionEndpointPopulationDosageImpactClaim #
diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
decrease
symptoms
patients with irritable bowel syndrome (IBS)
-
can be effective at symptom reduction
#1
positive control consisting of 5 g fructooligosaccharides (FOS) mixed in lactose-free milk
increase
breath hydrogen response
healthy adults
-
resulted in higher breath hydrogen response compared to all three of the low FODMAP ONS beverages
#2
low FODMAP oral nutrition supplements (ONS)
decrease
breath hydrogen response
healthy adults
-
resulted in a lower breath hydrogen response compared to the positive control
#3
three low FODMAP ONS formulas (A, B, and C) and a positive control
no change
GI symptom response
healthy adults
-
There were no differences in GI symptom response
#4
All treatments
neutral
tolerance
healthy participants
-
were well tolerated
#5
Abstract

BACKGROUND: There has been increasing interest in utilizing a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) for the treatment of irritable bowel syndrome (IBS), a functional gastrointestinal disease. While studies have indicated that this diet can be effective at symptom reduction, it is a restrictive diet and patients may find it challenging to find low FODMAP products to meet their nutrient needs. The primary objective of this study was to assess the gastrointestinal (GI) tolerance of three low FODMAP oral nutrition supplements (ONS) in healthy adults. METHODS: A double-blind randomized controlled crossover study was conducted in 21 healthy adults (19-32 years). Fasted subjects consumed one of four treatments at each visit, with a one week wash out period between visits. Each participant received all treatments. Treatments included three low FODMAP ONS formulas (A, B, and C) as well as a positive control consisting of 5 g fructooligosaccharides (FOS) mixed in lactose-free milk. Breath hydrogen was measured at baseline, 1, 2, 3, and 4 h post treatment consumption. Subjective GI symptom questionnaires were completed at baseline, 0.5, 1, 1.5, 2, 3, 4, 12, 24 and 48 h following treatment consumption. Mean breath hydrogen concentrations and baseline corrected area under the curve for both breath hydrogen and GI symptoms were analyzed and compared between treatments. Significance was determined at P < 0.05. RESULTS: The positive control resulted in higher breath hydrogen response compared to all three of the low FODMAP ONS beverages at 3 and 4 h after consumption. There were no differences in GI symptom response between treatments. CONCLUSIONS: All treatments were well tolerated in healthy participants. The low FODMAP formulas resulted in a lower breath hydrogen response compared to the positive control, and may be better tolerated in individuals with IBS. More research should be conducted to better understand the GI tolerance of low FODMAP ONS in individuals with IBS. TRIAL REGISTRATION: The protocol for this study was registered on ClinicalTrials.gov in January 2016 (Clinical Trials ID: NCT02667184 ).

Medical Subject Headings (MeSH)
AdolescentAdultAgedBody Mass IndexCross-Over StudiesDietDietary CarbohydratesDietary FatsDietary FiberDietary ProteinsDietary SupplementsDisaccharidesDouble-Blind MethodFemaleFermentationGastrointestinal TractHealthy VolunteersHumansIrritable Bowel SyndromeMaleMiddle AgedMonosaccharidesOligosaccharidesPolymersSurveys and QuestionnairesYoung Adult
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality85/10
Citation Metrics
Total Citations7
Citations/Year0.9
Relative Citation Ratio0.24
NIH Percentile12.5%
Research Impact Scores
APT Score0.25
Weight Score1.67
Normalized Score0.67
Related Supplements